NovaBay Pharmaceuticals Inc (NBY)

3.92
AMEX : Health Care
Prev Close 3.90
Day Low/High 3.80 / 4.00
52 Wk Low/High 1.62 / 5.29
Avg Volume 52.80K
Exchange AMEX
Shares Outstanding 15.13M
Market Cap 59.03M
EPS -6.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NovaBay Pharmaceuticals To Hold Third Quarter 2016 Conference Call On November 10

NovaBay Pharmaceuticals To Hold Third Quarter 2016 Conference Call On November 10

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces...

NovaBay Pharmaceuticals Successfully Regains Compliance With NYSE Continued Listing Requirements

NovaBay Pharmaceuticals Successfully Regains Compliance With NYSE Continued Listing Requirements

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that it has...

NovaBay Pharmaceuticals Receives $7 Million From Early Warrant Exercise

NovaBay Pharmaceuticals Receives $7 Million From Early Warrant Exercise

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that during the...

NovaBay Pharmaceuticals' Auriclosene® Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation

NovaBay Pharmaceuticals' Auriclosene® Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company, announces that data from a Phase 2b clinical study with Auriclosene Irrigating Solution (AIS) demonstrated statistically significant and...

NovaBay Pharmaceuticals' Neutrox® Product Line Receives CE Mark And ISO Certification For The European Union

NovaBay Pharmaceuticals' Neutrox® Product Line Receives CE Mark And ISO Certification For The European Union

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene in the domestic eye care market, announces that its...

NovaBay Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference

NovaBay Pharmaceuticals To Present At The Rodman & Renshaw Global Investment Conference

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® lid and lash hygiene for the domestic eye care market, announces that President and CEO Mark...

NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results

NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold Second Quarter 2016 Conference Call On August 11

NovaBay Pharmaceuticals To Hold Second Quarter 2016 Conference Call On August 11

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces that it...

NovaBay Pharmaceuticals Completes $11.8 Million Private Placement

NovaBay Pharmaceuticals Completes $11.8 Million Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces the closing of...

NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President And Chief Executive Officer

NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President And Chief Executive Officer

NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces the appointment of...

NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results

NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals Appoints Todd Zavodnick To Its Board Of Directors

NovaBay Pharmaceuticals Appoints Todd Zavodnick To Its Board Of Directors

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® lid and lash hygiene product for the domestic eye care market, announces the appointment of...

NovaBay Pharmaceuticals To Hold First Quarter 2016 Conference Call On May 12

NovaBay Pharmaceuticals To Hold First Quarter 2016 Conference Call On May 12

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces...

Clinical Data Presented At ARVO Showing NovaBay's Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90%

Clinical Data Presented At ARVO Showing NovaBay's Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90%

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Hygiene product for the domestic eye care market, announces the presentation...

NovaBay Pharmaceuticals Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement

NovaBay Pharmaceuticals Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has entered...

NovaBay Pharmaceuticals Announces Filing Of Annual Report On Form 10-K

NovaBay Pharmaceuticals Announces Filing Of Annual Report On Form 10-K

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) (the "Company") announces that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2015, included in the Company's Annual...

NovaBay Pharmaceuticals To Present At 28th Annual ROTH Conference

NovaBay Pharmaceuticals To Present At 28th Annual ROTH Conference

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announced that Chairman and...

NovaBay Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results

NovaBay Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical Company focusing on commercializing its prescription Avenova ® Lid and Lash Cleanser for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold 2015 Fourth Quarter And Full Year Conference Call On March 3

NovaBay Pharmaceuticals To Hold 2015 Fourth Quarter And Full Year Conference Call On March 3

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it will report...

NovaBay Pharmaceuticals Announces $2.83 Million Private Placement

NovaBay Pharmaceuticals Announces $2.83 Million Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has entered into...

NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales To Exceed $1.5 Million

NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales To Exceed $1.5 Million

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announces that U.

3 Biotech Stocks Under $10 to Trade for Big Breakouts

3 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering breakout trades.

NovaBay Pharmaceuticals Secures $3 Million Bridge Loan

NovaBay Pharmaceuticals Secures $3 Million Bridge Loan

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has secured a...

NovaBay Declares Reverse Stock Split

NovaBay Declares Reverse Stock Split

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) ("NovaBay" or the "Company"), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market,...

NovaBay Pharmaceuticals Announces Restructuring To Focus On Avenova Commercialization And Reports Third Quarter Financial Results

NovaBay Pharmaceuticals Announces Restructuring To Focus On Avenova Commercialization And Reports Third Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announces a corporate restructuring to focus on the commercialization of its prescription Avenova ® Lid and Lash Cleanser.

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 19

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 19

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it has...

New Study Shows Success Fighting Eye Mites

New Study Shows Success Fighting Eye Mites

Tiny eye mites cause serious eye problems for millions of Americans, but a new study being presented by Dr. Kathryn Najafi-Tagol at a major Ophthalmology meeting shows that those problems can be successfully managed with Avenova® eyelid cleanser from NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 16

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 16

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it has...